Logo image of MNMD

MIND MEDICINE MINDMED INC (MNMD) Stock Fundamental Analysis

NASDAQ:MNMD - Nasdaq - CA60255C8850 - Common Stock - Currency: USD

9.61  -0.11 (-1.13%)

After market: 9.6 -0.01 (-0.1%)

Fundamental Rating

2

MNMD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While MNMD seems to be doing ok healthwise, there are quite some concerns on its profitability. MNMD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MNMD has reported negative net income.
MNMD had a negative operating cash flow in the past year.
MNMD had negative earnings in each of the past 5 years.
MNMD had a negative operating cash flow in each of the past 5 years.
MNMD Yearly Net Income VS EBIT VS OCF VS FCFMNMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -43.20%, MNMD perfoms like the industry average, outperforming 45.08% of the companies in the same industry.
The Return On Equity of MNMD (-61.77%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -43.2%
ROE -61.77%
ROIC N/A
ROA(3y)-48.75%
ROA(5y)-48.92%
ROE(3y)-68.39%
ROE(5y)-62.24%
ROIC(3y)N/A
ROIC(5y)N/A
MNMD Yearly ROA, ROE, ROICMNMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MNMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MNMD Yearly Profit, Operating, Gross MarginsMNMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for MNMD has been increased compared to 1 year ago.
The number of shares outstanding for MNMD has been increased compared to 5 years ago.
The debt/assets ratio for MNMD has been reduced compared to a year ago.
MNMD Yearly Shares OutstandingMNMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MNMD Yearly Total Debt VS Total AssetsMNMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

MNMD has an Altman-Z score of 2.11. This is not the best score and indicates that MNMD is in the grey zone with still only limited risk for bankruptcy at the moment.
MNMD has a Altman-Z score of 2.11. This is in the better half of the industry: MNMD outperforms 65.28% of its industry peers.
A Debt/Equity ratio of 0.22 indicates that MNMD is not too dependend on debt financing.
The Debt to Equity ratio of MNMD (0.22) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Altman-Z 2.11
ROIC/WACCN/A
WACCN/A
MNMD Yearly LT Debt VS Equity VS FCFMNMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

MNMD has a Current Ratio of 4.98. This indicates that MNMD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.98, MNMD is in the better half of the industry, outperforming 69.95% of the companies in the same industry.
MNMD has a Quick Ratio of 4.98. This indicates that MNMD is financially healthy and has no problem in meeting its short term obligations.
MNMD has a better Quick ratio (4.98) than 70.98% of its industry peers.
Industry RankSector Rank
Current Ratio 4.98
Quick Ratio 4.98
MNMD Yearly Current Assets VS Current LiabilitesMNMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

MNMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.57%, which is quite impressive.
EPS 1Y (TTM)40.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-92.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 23.43% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y29.63%
EPS Next 2Y9.85%
EPS Next 3Y9.08%
EPS Next 5Y23.43%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MNMD Yearly Revenue VS EstimatesMNMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
MNMD Yearly EPS VS EstimatesMNMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MNMD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MNMD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MNMD Price Earnings VS Forward Price EarningsMNMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNMD Per share dataMNMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.85%
EPS Next 3Y9.08%

More info and screens

0

5. Dividend

5.1 Amount

MNMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIND MEDICINE MINDMED INC

NASDAQ:MNMD (8/15/2025, 8:00:01 PM)

After market: 9.6 -0.01 (-0.1%)

9.61

-0.11 (-1.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-31 2025-07-31/amc
Earnings (Next)11-05 2025-11-05
Inst Owners55.16%
Inst Owner Change-26.57%
Ins Owners1.06%
Ins Owner Change16.26%
Market Cap731.22M
Analysts85.33
Price Target25.5 (165.35%)
Short Float %15.02%
Short Ratio8.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.47%
Min EPS beat(2)-34.51%
Max EPS beat(2)27.56%
EPS beat(4)2
Avg EPS beat(4)-9.34%
Min EPS beat(4)-35.89%
Max EPS beat(4)27.56%
EPS beat(8)4
Avg EPS beat(8)-14.58%
EPS beat(12)6
Avg EPS beat(12)-8.25%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.99%
PT rev (3m)4.17%
EPS NQ rev (1m)-31.91%
EPS NQ rev (3m)-29.15%
EPS NY rev (1m)0%
EPS NY rev (3m)8.35%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.94
P/tB 4.42
EV/EBITDA N/A
EPS(TTM)-1.45
EYN/A
EPS(NY)-1.65
Fwd EYN/A
FCF(TTM)-1.33
FCFYN/A
OCF(TTM)-1.33
OCFYN/A
SpS0
BVpS2.44
TBVpS2.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.2%
ROE -61.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.75%
ROA(5y)-48.92%
ROE(3y)-68.39%
ROE(5y)-62.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.98
Quick Ratio 4.98
Altman-Z 2.11
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-92.31%
EPS Next Y29.63%
EPS Next 2Y9.85%
EPS Next 3Y9.08%
EPS Next 5Y23.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-44.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-43.45%
EBIT Next 3Y-12.96%
EBIT Next 5Y29.36%
FCF growth 1Y-105.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-105.88%
OCF growth 3YN/A
OCF growth 5YN/A